{"id":72300,"date":"2026-08-11T13:41:49","date_gmt":"2026-08-11T05:41:49","guid":{"rendered":"https:\/\/flcube.com\/?p=72300"},"modified":"2026-08-11T13:41:50","modified_gmt":"2026-08-11T05:41:50","slug":"grit-biotechnology-and-drug-farm-sign-deep-collaboration-agreement-to-co-create-kunevo-an-ai-native-biotech-rd-platform-for-first-in-class-drug-discovery","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72300","title":{"rendered":"GRIT Biotechnology and Drug Farm Sign Deep Collaboration Agreement to Co\u2011Create KunEvo, an AI\u2011Native Biotech R&D Platform for First\u2011in\u2011Class Drug Discovery"},"content":{"rendered":"\n

GRIT Biotechnology<\/strong> and Sino-US biotech company Drug Farm<\/strong> jointly announced a deep agreement to collaborate on the development and commercialization of an AI\u2011native platform<\/strong>, the companies said. The two companies will co\u2011create a world\u2011leading AI\u2011native biotech R&D platform named KunEvo<\/strong>.<\/p>\n\n\n\n

Deal Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Parties<\/strong><\/td>GRIT Biotechnology \u00d7 Drug Farm (Sino\u2011US biotech)<\/td><\/tr>
Deal Type<\/strong><\/td>Deep collaboration agreement on development and commercialization of an AI\u2011native platform<\/td><\/tr>
Platform Name<\/strong><\/td>KunEvo<\/strong><\/td><\/tr>
Positioning<\/strong><\/td>World\u2011leading AI\u2011native biotech R&D platform<\/td><\/tr>
Announcement Date<\/strong><\/td>24 Jul 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Platform Scope \u2013 KunEvo<\/h2>\n\n\n\n

KunEvo is designed to accelerate the industrial application of underlying AI for Science technologies<\/strong> across three frontier areas:<\/p>\n\n\n\n

Focus Area<\/th>Objective<\/th><\/tr><\/thead>
First\u2011in\u2011Class Novel Target Discovery<\/strong><\/td>Identify and validate novel drug targets via AI\u2011driven discovery<\/td><\/tr>
Tumor Cell Therapies<\/strong><\/td>Accelerate development of cell\u2011based cancer therapies<\/td><\/tr>
Neoantigen Cancer Vaccines<\/strong><\/td>Enable AI\u2011powered design of personalized neoantigen vaccines<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Core Innovation \u2013 Bridging Dry Lab and Wet Lab<\/h2>\n\n\n\n

By bridging the gap between dry\u2011lab computation and wet\u2011lab experimentation<\/strong>, the partners aim to propel drug R&D from traditional monthly iteration cycles<\/strong> into a new era of real\u2011time, second\u2011by\u2011second iterations<\/strong>.<\/p>\n\n\n\n

Traditional R&D<\/th>KunEvo Target Paradigm<\/th><\/tr><\/thead>
Monthly iteration cycles<\/td>Real\u2011time, second\u2011by\u2011second iterations<\/td><\/tr>
Disconnected computation and experimentation<\/td>Integrated dry\u2011lab \/ wet\u2011lab closed loop<\/td><\/tr>
Sequential discovery workflows<\/td>Parallel AI\u2011driven discovery and validation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale & Market Impact<\/h2>\n\n\n\n